Brad Thomson is currently the CEO and Co-founder, Wyvern Pharmaceuticals Inc., and Kickshaw Ventures Ltd. He has been involved with biotechnology ventures for nearly 40 years, including 23 years as CEO of two NASDAQ listed biotech companies. He has founded and cofounded 18 biotech companies, of which nine went on to be publicly listed, and five were acquired by other companies. His areas of interest have been in autoimmune disease, oncology, and infectious diseases. His areas of expertise include, immunotherapy, oncology, infectious disease, autoimmune disease, corporate planning, strategic planning, M&A, and raising capital.